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Abstract 
Objectives: To investigate relationship between periprostatic adipose tissue (PPAT) 
adipokines expression and PCa aggressiveness using both pathological features of radical 
prostatectomy (RP) and multiparametric MRI parameters.  
Patients and methods: Sixty-nine men were recruited to assess immunohistochemical 
expression of TNFα- and VEGF of periprostatic fat of radical prostate specimens.  Percent 
immunopositivity was quantified on scanned slides using Aperio Positive Pixel Count 
algorithm for PPAT TNFα, VEGF and androgen receptors. Periprostatic fat volume 
(PFV) was segmented on contiguous T1-weighted axial MRI slices from the level of the 
prostate base to apex. PFV was normalised to prostate volume (PV) to account for 
variations in PV (NPFV=PFV/PV). MRI quantitative values (Kep, Ktrans, and ADC) were 
measured from PCa primary lesion using OleaSphere software. Patients were stratified 
into three groups according to RP GS: ≤6, 7(3+4) and 7(4+3) or more.  
Results: The mean rank of VEGF and TNFα were significantly different between the 
groups [H(2)= 11.038, p=0.004] and [H(2)=13.086, p=0.001], respectively. Patients with 
stage pT3 had higher TNFα (18.2±8.95) positivity than patients with stage pT2 
(13.27±10.66), t (67) =-2.03, p=0.047. TNFα expression significantly correlated with 
Ktrans (ρ=0.327, p=0.023). TNFα (p=0.043) and VEGF (p= 0.02) correlates with high-
grade PCa (GS≥7) in radical prostatectomy specimens and correlated significantly with 
upgradation of Gleason score from biopsy to radical prostatectomy histology.  
Conclusions:  Expression level of TNFα and VEGF on immunostaining significantly 
correlated with aggressivity of PCa. As biomarkers, these suggest the risk of having high-
grade PCa in men undergoing RP.  
 
 
 
Keywords: prostate cancer; periprostatic adipose tissue; TNFα; VEGF; MRI; radical 
prostatectomy 
 
 
 
 - 2 - 
1 Introduction  
Several studies have found an association between periprostatic fat adiposity and the 
aggressivity of prostate cancer (PCa) using several different imaging modalities and 
measurement techniques [1-3]. In a recent MRI study, we found normalised periprostatic 
fat volume (NPFV) to be a significant predictor for high-grade localised prostate cancer 
in men opting for radical prostatectomy [4]. However, imaging alone cannot discriminate 
between metabolically more active and less active periprostatic adipose tissue (PPAT).  
Adipocytes have an important role in synthesizing and storing triglycerides from free 
fatty acids (FFA) and in producing adipokines [5-8]) have reported that there are two 
kinds of adipocytes: “fat” and “thin”. Besides being storage cells for free-fatty acids (the 
major source of energy for the cancer cell), the more active “fat” cells, which are common 
in obese populations, may differentiate into “cancer-associated adipocytes” and crosstalk 
with cancer cells via a paracrine effect, resulting in the secretion of more inflammatory 
adipokines and chemokines (e.g. CCL7), stimulating macrophage infiltration, which in 
turn encourages insulin resistance that leads to disease progression and local 
dissemination [5, 8-13].  
Periprostatic adipose tissue inflammation has been found to be associated with high-grade 
PCa [14]. When adipose tissue expands, hypoxia occurs, and certain adipokines become 
up-regulated. In response, hypoxia inducible factor 1 alpha (HIF-1α), may interact with 
endothelial cells and lead to a reduction in nitric oxide that regulates vasodilation, 
stimulates angiogenesis and increases vascular permeability to overcome the hypoxia 
[15-17]. Tumour necrosis factor alpha (TNFα) and vascular endothelial growth factor 
(VEGF) are adipokines which have been widely implicated for their roles in 
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tumourigenesis by inducing inflammatory and angiogenic responses, respectively, and 
increasing the risk of metastasis [18-24].  
Angiogenesis in periprostatic fat may facilitate the seeding of a PCa microenvironment 
with adipocyte precursors (lipoblasts), that secrete numerous factors (e.g. IL-6 and TNFα) 
involved in the inflammatory response, particularly in pathological conditions such as 
obesity [25]. Zhang et al [26] have described that the tumour microenvironment may 
contain lipoblasts seeded by visceral fat (VF) through blood vessels. It was suggested that 
periprostatic fat has more lipoblasts than VF [27]. Thus, periprostatic fat could be a major 
source for seeding the microenvironment of PCa with lipoblasts, facilitating tumour 
progression. Understanding the metabolic pathways between PPAT, as an inflammatory 
promotor, and PCa could reveal new diagnostic and therapeutic possibilities. Anti-
angiogenic treatments, in combination with radiotherapy, could be successful ways to 
treat PCa [28]. 
This study aimed to: 
1. Investigate the correlation between PPAT metabolic activity and prostate cancer 
aggressiveness by comparing inflammatory and angiogenic adipokine (TNFα and 
VEGF) expression levels in the periprostatic fat with Gleason scores (GS) and 
pathological tumour staging (pT).  
2. Correlate expression level of adipokines (TNFα and VEGF) with quantifiable 
MRI parameters of PCa aggressivity.
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2 Patients, materials and methods 
2.1 Cohort selection and power calculation 
This was a prospective study with institutional approval (Caldicott/CSAppGN021211) for 
follow-up. A sample size of 69 was calculated based on information from a pilot phase of the 
study (n = 15) and a power calculation (Table S1). The pilot phase also evaluated the quality 
of immunostaining. Between January 2010 and December 2015, we recruited 69 men with 
localised prostate cancer opting for RP. Demographic details were recorded in a database. 
Periprostatic-fat tissue sections were selected from the excised prostate surface at three or more 
different periprostatic regions. Tissue block sectioning and immunohistochemistry (IHC) were 
performed at the Tayside Tissue Biorepository (TBR), Study inclusion criteria were:  
• Men with localised prostate cancer (PCa) who underwent Radical Prostatectomy (RP).  
• Gleason score and histopathological stage of RP specimens reported and discussed at 
multidisciplinary meetings by an experienced uropathologist.  
Exclusion criteria were: men with metastatic PCa or those with localised disease who had 
external beam radiotherapy/brachytherapy or focal treatment prior to radical surgery.  Men 
were also excluded if they had hormones in neoadjuvant settings.  
The primary aim of the study was evaluation of the magnitude of correlation between the 
immunohistochemical expression of PPAT and histopathological parameters of PCa. The 
correlation between quantitative MRI parameters and adipokine expression levels was the 
secondary aim (Figure S1).   
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2.2 Antibody selection and immunohistochemistry preparation 
Table S2 summarises the characteristics of the selected antibodies. Antigen retrieval and 
deparaffinisation were performed using a DAKO EnVision™ FLEX Target Retrieval solution 
(high pH) buffer (50x conc.) (K8004) in a DAKO PT Link (serial number PT2794Y1205) for 
10 minutes at 97°C. Immunostaining using the DAKO EnVision™ FLEX system on a DAKO 
Autostainer Link 48 (serial number AS2383D1203) was conducted according to the 
manufacturer’s protocol. Sections were initially washed in a Flex Wash Buffer (K8006). Table 
S3 summarises the protocols used for TNFα, VEGF, and AR.  
2.3 Immunohistochemistry Analysis 
After IHC application, the stained sections were scanned at 40x magnification using a Leica 
Aperio® slide scanner and the results assessed employing the local ImageScope (version 
12.3.2.1813) for staining quality assessment and the linked online eSlide Manager (version 
12.1.0.5029) for digital analysis.  
The region of periprostatic adipose tissue (PPAT) was manually selected from different 
periprostatic regions.  An experienced pathologist (SF) reviewed histopathology reviewed 
histopathology and guided selection of regions specifically but not exclusively around tumour 
within the prostate gland.  We did not include damaged adipose tissue at section edges, blood 
vessels, and artefacts. The selected total area on each slide was not less than 30,000m2. 
Following standardised parameters, we used the Leica Aperio Positive Pixel Count algorithm 
to quantify the positive and negative staining of 3,3’-diaminobenzidine (DAB) and 
Hematoxylin (counterstain), respectively (Figure 1). The algorithm automatically analysed the 
positive DAB staining of the selected regions into three different coloured pixels: strong 
positive (Sp) (red), positive (p) (orange), and weak positive (Wp) (yellow). The Hematoxylin 
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counterstain was represented by blue negative pixels. At the same time, the positivity (%) was 
calculated [Positivity (%) = (Wp + p + Sp) / Ntotal x 100] (Figure 2), where Ntotal is the total 
number of positive and negative pixels in the selected regions. The positivity (%) represents 
the concentration of the protein in PPAT.  
Reproducibility of the slide digital analysis was assessed in a subgroup of 14 randomly selected 
patients by repeated measures in two-week intervals. An excellent interrater reliability was 
shown with an intraclass correlation coefficient of 0.951 in single measures (p < 0.001). 
2.4 MRI technique 
The full MRI protocol is detailed elsewhere [4]. PFV was determined using a semi-automated 
segmentation technique on contiguous T1-weighted axial MRI slices from the level of the 
prostate base to the apex. PFV was normalised to prostate volume (PV) to account for 
variations in PV (NPFV=PFV/PV). High-resolution T2 weighted scans and apparent diffusion 
coefficient (ADC) maps derived from diffusion weighted imaging (DWI) were used for 
identification of the index PCa lesion by an experienced uroradiologist. Subsequently, in 48 
patients who underwent dynamic contrast enhancement, quantitative parameters (Ktrans and 
Kep) were extracted with OleaSphere software version 3.0 (Olea Medical, La Ciotat, France). 
2.5 Statistical Analyses 
Patients were stratified into three groups according to the Gleason score of the final 
prostatectomy specimen: ≤6, 7(3+4) and 7(4+3) or more. The association between the three 
groups and adipokine expression levels including AR and clinical and pathological data was 
determined using Kruskal-Wallis and one-way analysis of variance (ANOVA) tests for 
parametric and non-parametric continuous variables, respectively, and Chi-square test for 
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categorical variables (WHO weight classification, pT stage and D’Amico risk classification). 
Receiver Operating Characteristic (ROC) curve analysis was used to test the ability of TNFα 
and VEGF to differentiate between high-grade (GS ≥ 7) and low-grade (GS ≤ 6) prostate 
cancers. Binary logistic regression analysis was used to establish an independent effect of 
TNFα and VEGF on high-grade (GS ≥ 7) vs low-grade (GS ≤ 6) prostate cancers. Independent 
sample t-test was used to compare the adipokine levels, AR, functional MRI quantitative values 
(Ktrans, Kep, and ADC value) and age with pT and GS upgrading from biopsy specimen to RP. 
Spearman correlation coefficients (ρ) were used to evaluate the relationship between the 
adipokine levels (TNFα and VEGF), AR, MRI parameters (Ktrans, Kep, and ADC value), NPFV 
and pre- and post-operative GS. p value of < 0.05 was considered statistically significant. IBM 
Statistical Package for the Social Sciences (SPSS) (version 23) for OS X was used for data 
analyses.  
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3 Results 
The mean age of the cohort (N=69) was 66.13 ± 5.47 years (range, 53-78), and the mean BMI 
was 28.12 ± 4.37 kg/m2
 
(range, 20.5 - 40.6). According to WHO classification, 17 patients 
were classified as normal weight (27.86 %), 27 as overweight (44.26%), 13 as obese class I 
(21.31 %), three as obese class II (4.93 %), and 1 as obese class III (1.64%). Table 1 
summarises the patients’ characteristics categorised into three groups according to the post-
operative GS based on histopathology.  
The mean ranks of the positivity of vascular endothelial growth factor (VEGF) and tumour 
necrosis alpha (TNFα) were statistically different between the three groups (GS ≤ 6, GS = 
7(3+4) and GS ≥ 7(4+3), with [H (2) = 11.038, p = 0.004] and [H (2) = 13.086, p = 0.001], 
respectively (Figure 3). There were no differences in the mean ranks of immunopositivity for 
AR between the three groups [H (2) = 1.388, p = 0.5], nor in mean age [H (2) = 1.880, p = 
0.391] (Table 1).  
After dichotomisation of PCa histopathology into low (GS ≤ 6) and high (GS ≥ 7) grade groups, 
ROC curve analysis yielded areas under the curves for TNFα and VEGF of 0.897 (p = 0.001) 
and 0.910 (p = 0.001), with Youden’s indices of 9.03 and 4.22, respectively. Use of these cut-
offs provided a sensitivity and specificity for differentiating between low and high-grade 
cancers of 74.6% and 100%, respectively for TNFα and 85.7% and 100%, respectively for 
VEGF (Figure 4).   
Binary logistic regression analysis showed that both TNFα and VEGF could predict the risk of 
having high-grade PCa (GS ≥ 7), with odds ratios (OR) of 1.343 (95% CI, 1.01-1.79; p = .043) 
and 1.921 (95% CI, 1.11-3.33; p = .02), respectively. A Hosmer-Lemeshow test revealed that 
the data fit the model well [𝝌2(8) = 1.81, p = 0.986]. 
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Patients with stage pT3 had statistically significantly higher positivity of TNFα (18.2 ± 8.95) 
than patients with stage pT2 (13.27 ± 10.66), t (67) = -2.03, p = 0.047. There was no relationship 
between AR and VEGF and pT stage of PCa, [t (67) = .458, p = 0.649] and [t (67) = -.547, p = 
0.586], respectively).  
Mean expression levels of TNFα and VEGF for Gleason score ≤ 6 disease were 4.1 (± 3.7) and 
2.8 (±1.1) respectively. In contrast mean levels of expression for TNFα and VEGF for Gleason 
score 7 and more disease were 15.4 (±9.7) and 15.1 (±11.3) respectively.  There were 22 
(31.8%) patients with upgraded GS from biopsy specimen to final RP (14 had Gleason score 6 
disease on biopsies and were upgraded to GS 7 or more).  Analysis of 20 radical prostatectomy 
cases (20/69; 28.9%) diagnosed with Gleason 6 on biopsies showed that 70% (14/20; 70%) 
were upgrade to Gleason 7 or more on final histopathology. Performance of expression level 
analysis for TNF α and VEGF in those with upgraded disease vs. non-upgraded disease showed 
statistically significant differences (Table 2).  VEGF expression between the non-upgraded 
(2.83 ± 1.18; n = 6) and upgraded (6.85 ± 3.45; n = 14) groups was statistically significant [t 
(18) = -2.75, p = 0.013]. Similarly, there was a difference in the mean of TNF α expression 
between the non-upgraded (4.11 ± 3.77; n = 6) and upgraded (10.55 ± 8; n = 14) groups with 
statistically significance [t (18) = -1.86, p = 0.039].  This suggests a high expression of TNFα 
and VEGF in presence of low grade disease on biopsy may indicate presence of high grade 
disease in the prostate.   
Immunohistochemical expression of TNFα was significantly positively correlated with Ktrans 
(ρ = 0.327, p = 0.023), but not with Kep (ρ = 0.162, p = 0.270) or ADC value (ρ = -0.096, p = 
0.516). There was no significant correlation between VEGF expressions with any of 
quantitative MRI parameters. Table 3 summarises the correlations results.  
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4 Discussion 
To our knowledge, this is the first study to investigate the relationship between the 
inflammatory and angiogenic adipokine (TNFα and VEGF) expression levels in PPAT and the 
aggressivity of PCa by comparing their immunohistochemical expression with Gleason scores 
(GS), pathological tumour staging (pT), and quantifiable MR imaging biomarkers. The results 
indicate a strong correlation between PPAT TNFα positivity and histopathological GS, as well 
as pT stage. We observed that both TNFα and VEGF were significant correlating with the risk 
of having high-grade PCa (GS ≥ 7) following RP. However, PPAT androgen receptor 
expression had no relationship with either post-operative GS or pT stage.  It is, however 
interesting to observe that men who were upgraded from low GS on biopsy had statistically 
significant different level of expression for both TNFα and VEGF to those who continued to 
have low grade disease with similar GS on biopsy and radical prostatectomy histology.   
Recent studies [1, 3, 29-31], including our previous study [4], have confirmed the relationship 
between the adiposity of periprostatic fat and the aggressivity of PCa. The cross-talk between 
PPAT and PCa cells could modify the phenotype and characteristics of closely related 
adipocytes, which can become more metabolically active adipocytes called “cancer-associated 
adipocytes” [11, 12]. These cells can stimulate and support PCa progression by releasing FFA, 
the major source of PCa energy, through lipolysis and secreting adipokines that stimulate 
tumour progression through a paracrine effect [12, 32]. This may suggest that both adiposity 
and adipokine activity of periprostatic fat have an impact on the aggressivity of PCa. However, 
at present, imaging is unable to assess adipokine activity of periprostatic fat.  Interestingly, 
BMI, the marker of generalised obesity, has no relationship with NPFV nor PCa aggressiveness 
indicating that periprostatic fat adiposity is more important than BMI [4].  
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TNFα is a pro-inflammatory and lipolytic adipokine that induces apoptosis and inhibits 
carbohydrate metabolism and adipogenesis [33-37]. Serum TNFα has been reported as a 
biomarker for PCa diagnosis [20]. As a pro-inflammatory cytokine, it can influence PCa 
progression and increase the risk of metastasis [19, 23, 24]. Focusing on PPAT, a study showed 
that inflammation was associated with high-grade PCa [14]. PPAT TNFα is higher in obese 
men, which contributes to insulin resistance [9, 35, 38-40], but it is not associated with lipolysis 
in cachectic patients with gastrointestinal cancers [36].   Ribeiro et al [41] have reported that 
TNFα was expressed by approximately 1.7-fold higher in PPAT explants stimulated with a 
PC3 human PCa cell line conditioned medium, but not by stromal vascular fractions that did 
not contain mature adipocytes, suggesting that mature PPAT adipocytes, the cancer-associated 
adipocytes, can significantly crosstalk with PCa cells and secrete larger amount of TNFα [11]. 
Therefore, we investigated its relation to PCa grading along with staging and found that it was 
significantly correlated with the both.  
Ktrans, representing the rate of accumulation of gadolinium-based contrast agent in the 
extravascular extracellular space, is a measure of capillary permeability. Our study showed that 
Ktrans in the primary lesion was significantly correlated with PPAT TNFα but not to PPAT 
VEGF. This may reflect the consequence of the inflammatory response of PPAT and increased 
vascular permeability leading to transfer of the contrast agent from blood vessels to the 
extracellular matrix. It has been reported that PPAT angiogenesis may facilitate seeding of a 
PCa microenvironment with adipocyte precursors (lipoblasts) [42].  These lipoblasts secrete 
numerous factors (e.g. IL-6 and TNFα) involved in the inflammatory response, particularly in 
obesity [25]. Taking all of this into consideration, there is a clear implication that TNFα has a 
significant role as a pro-inflammatory adipokine, secreted by activated mature PPAT 
adipocytes, together with the angiogenic PPAT VEGF, creating a favourable stromal 
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microenvironment that promotes PCa progression by inducing vascularity and increasing 
vascular permeability [43-50], which facilitates seeding PPAT lipoblasts to the PCa tumour 
stromal microenvironment [42]. Moreover, as a lipolytic factor, PPAT TNFα may increase the 
release of FFA, which has been found to be the major source of PCa energy[32].   The 
quantitative Ktrans of primary prostate lesion could provide an estimate of angiogenic activity 
of periprostatic fat, however this needs further research.  
Our results showed that both TNFα and VEGF positivity at IHC can distinguish between low 
(GS ≤ 6) and high (GS ≥ 7) grade PCa.  TNFα and VEGF expression levels above 9.03% and 
4.22% had a 74.6% and 85.7% chance of having high-grade PCa, respectively. These findings 
have strong clinical implications, if externally validated to predict upgrading from GS biopsy 
to RP, the practical utility of measuring the expression of TNFα and VEGF in the periprostatic 
fat sample during prostate biopsy could be realised, and the level of expression for both could 
become a marketable test, similar to Oncotype DX, Prolaris, and Decipher tests, that predict 
upgrading and help in decision-making such as in active surveillance versus radical treatment 
[51].  
Androgens upregulate the adrenoreceptors of catecholamines in adipose tissue, and their 
receptors are more prominent in visceral fat than subcutaneous fat [52, 53]. This may indicate 
the uptake of the lipolytic catecholamines in visceral fat is higher, leading to the release of 
greater amounts of FFA, the major source of PCa energy [32, 52, 53]. Therefore, we included 
PPAT AR in our analysis, but did not find any correlation with GS or pT stage. 
There are some limitations to our study. The present investigation was a single centre cohort 
and the results require further validation through a multicentre design. Quantitative MRI data 
was available for only 48 cases in the cohort (we had no imaging data for the remaining 21 
cases as they were scanned on 1.5T MRI).  Though we demonstrated no correlation between 
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PPAT VEGF and Ktrans of the primary lesion at MRI, a larger sample size might have altered 
this result.  Although we had only 6 patients in Gleason score 6 diseases, trends do suggest that 
periprostatic fat biopsies at the time of prostatic biopsy for immunostaining for inflammatory 
biomarkers could represent a time-saving way of obtaining useful information and predicting 
aggressive PCa.     
In conclusion, PPAT TNFα and VEGF immunostaining was significantly positively correlated 
with the aggressivity of PCa (grade and stage) in men undergoing radical prostatectomy for 
clinically localised disease. As PCa biomarkers, PPAT metabolic activity measured by 
immunohistochemical expression of TNFα and VEGF significantly correlates with the risk of 
having high-grade prostate cancer disease including upgradation from prostate biopsy results. 
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Figure 1: (I) Periprostatic adipose tissues were manually selected from multiple areas proximal and 
distal to the prostate tissue (red marks). The Positive Pixel Count algorithm was used to quantify the 
positive and negative staining within the selected regions. (II) A closer view of the net-shaped adipose 
tissue analysed by the Positive Pixel Count algorithm. Lipid droplets were not included in the analysis. 
Artefacts, blood vessels, and other types of tissues within the selected regions were manually excluded 
(green marks). 
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Figure 2: (I) Manually selected periprostatic adipose tissue before analysis. (II) After running the 
Positive Pixel Count algorithm, the positive DAB staining (I) of the selected region was divided into 
3 different coloured pixels (yellow for weak positive; orange for positive; red for strong positive) based 
on standardised levels of intensity (the concentration of DAB staining). The Hematoxylin counterstain 
was represented by blue negative pixels. The positivity (%) was calculated by dividing the number of 
positive pixels by the total pixel count within the selected region and multiplying by 100. 
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Figure 3: Box plot showing the differences in the distribution and the median of the positivity of 
vascular endothelial growth factor (VEGF) and tumour necrosis factor alpha (TNFa) in the three groups 
stratified according to post-operative Gleason score. 
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Figure 4: ROC curve showing the areas under the curves of tumour necrosis factor alpha (TNFa; 
green line) and vascular endothelial growth factor (VEGF; blue line). 
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Table 1: Patient characteristics. 
  
 
Group 1 
Post-operative 
Gleason score 
6 
Group 2 
Post-operative 
Gleason score 7 
(3+4) 
Group 3 
Post-operative 
Gleason score 7 
(4+3) and over 
p value 
Mean  Standard Deviation 
No. n = 6 n = 35 n = 28  
Age 64  8.17 65.83  5.67 66.96  4.54 .391a 
VEGF (%) 2.83  1.18 10.03  7.74 9.45  6.65 .004b 
AR (%) 7.44  5.07 5.64  3.71 7.15  5.96 .500b 
TNFa (%) 4.1  3.77 14.89  10.76 18.32  8.75 .001b 
Initial PSA 
(ng/ml) 
7.9  2.13 10.69  7.53 11.53  6.39 .317b 
PV (cm3) 64.64  8.74 48.99  26.035 55.44  23.01 .165b 
WHO classification N (%)* 
No. n = 4 n = 33 n = 24 
.568c 
Normal weight 1 (25) 10 (30.3) 6 (25) 
Overweight 3 (75) 16 (48.5) 8 (33.3) 
Obesity class I 0 5 (15.2) 8 (33.3) 
Obesity class II 0 2 (6.1) 1 (4.2) 
Obesity class III 0 0 1 (4.2) 
Pathological stage N (%)* 
No.  n = 6 n = 35 n = 28 
.027c T2 5 (83.3) 24 (68.6) 11 (39.3) 
T3 1(16.7) 11 (31.4) 17 (60.7) 
D’Amico risk classification N (%)* 
No.  n = 6 n = 35 n = 28 
<.001c 
Low  5 (83.3) 9 (25.7) 1 (3.6) 
Intermediate 1 (16.7) 17 (48.6) 10 (35.7) 
High 0 9 (25.7) 17 (60.7) 
VEGF = Vascular endothelial growth factor; AR = Androgen receptors; TNFa = Tumour 
necrosis factor alpha; PSA = Prostate specific antigen; PV = Prostate volume. 
Patients were stratified according to post-operative Gleason score 
aANOVA, bKruskal-Wallis test, c𝝌2 test 
*(%) within each group 
p value is significant <0.05 
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Table 2. Independent-sample t test was used to compare the differences in the mean adipokine 
Immunopositivity (%) for upgraded and not upgraded from low-grade (GS = 3+3) PCa at 
biopsy (n = 20). 
 N Mean 
(%) 
Std. Deviation 
(%) 
Std. Error 
Mean (%) 
t *p value 
VEGF not upgraded 6 2.83 1.18 .48 
-2.75 .013 
upgraded 14 6.85 3.45 .92 
TNFa not upgraded 6 4.11 3.77 1.53 
-1.86 .079 
upgraded 14 10.55 8 2.14 
(%) immunopositivity within each group 
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Table 3: The relationship between periprostatic adipose tissue adipokines (VEGF and TNFa), androgen receptors, age, prostate volume, 
Quantitative values of functional MRIs (DCE-MRI and DWI), fat measures, body mass index (BMI), prostate specific antigen (PSA) and pre- and 
post-operative Gleason scores using Spearman correlation coefficient. 
 AR VEGF TNFa Age PV AFA SFT PSA BMI Ktrans Kep ADC NPFV 
Post-op 
GS 
Biopsy 
GS 
Spearman's 
rho 
AR Correlation Coefficient 1.000 .269* .226 .190 .057 .112 .062 .101 .107 .194 .084 .302* .018 .045 .103 
Sig. (2-tailed) . .025 .062 .119 .653 .383 .629 .408 .411 .185 .572 .037 .886 .714 .399 
N 69 69 69 69 64 63 63 69 61 48 48 48 64 69 69 
VEGF Correlation Coefficient .269* 1.000 .475** .009 -.143 .040 .127 .175 .110 .158 .118 .012 .068 .190 .265* 
Sig. (2-tailed) .025 . .000 .943 .259 .757 .320 .151 .397 .284 .426 .933 .595 .117 .028 
N 69 69 69 69 64 63 63 69 61 48 48 48 64 69 69 
TNFa Correlation Coefficient .226 .475** 1.000 -.012 -.038 .156 .278* .177 .233 .327* .162 -.096 .082 .345** .419** 
Sig. (2-tailed) .062 .000 . .921 .767 .223 .027 .146 .070 .023 .270 .516 .517 .004 .000 
N 69 69 69 69 64 63 63 69 61 48 48 48 64 69 69 
Ktrans 
Correlation Coefficient .194 .158 .327* .126 .159 .070 .089 .060 .115 1.000 .682** .081 .157 .005 .110 
Sig. (2-tailed) .185 .284 .023 .395 .281 .640 .551 .687 .443 . .000 .588 .286 .974 .458 
N 48 48 48 48 48 47 47 48 47 48 48 47 48 48 48 
Kep 
Correlation Coefficient .084 .118 .162 .032 .211 -.106 .061 .011 .051 .682** 1.000 .122 .057 -.123 .054 
Sig. (2-tailed) .572 .426 .270 .828 .150 .480 .683 .941 .735 .000 . .413 .701 .405 .716 
N 48 48 48 48 48 47 47 48 47 48 48 47 48 48 48 
ADC Correlation Coefficient .302* .012 -.096 .067 -.068 -.221 -.334* -.230 -.365* .081 .122 1.000 -.163 -.473** -.361* 
Sig. (2-tailed) .037 .933 .516 .651 .644 .136 .022 .116 .012 .588 .413 . .268 .001 .012 
N 48 48 48 48 48 47 47 48 47 47 47 48 48 48 48 
AR = Androgen receptors; VEGF = Vascular endothelial growth factor; TNFa = Tumour necrosis factor alpha; PV = Prostate volume; AFA = Abdominal fat area; SFT = 
Subcutaneous fat thickness; PSA = Prostate specific antigen; BMI = Body mass index; Ktrans = Transfer constant; Kep = Reverse reflux rate constant; ADC = Apparent diffusion 
coefficient; NPFV = Normalised periprostatic fat volume; GS = Gleason score.  
*. Correlation is significant at the 0.05 level (2-tailed).  
**. Correlation is significant at the 0.01 level (2-tailed). 
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Figure S1: Schematic diagram showing the primary and secondary outcomes of this study.
The histological parameters of 
prostate cancer: 
• Post-operative Gleason score. 
• Pathological tumour staging 
Primary 
outcome 
Secondary 
outcome 
Immunopositivity of periprostatic adipose tissue 
adipokines (TNFα and VEGF)  
Multiparametric MRI parameters 
(Ktrans, Kep and ADC value) 
Normalised periprostatic fat 
volume and other fat 
measures 
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Table S1: Power analysis. 
Fat measures Effect 
Size (f) 
 error 
probability 
Power (1- 
error 
probability) 
Sample size 
calculated 
p valuea 
 
AR .46 .05 .8 51 .249 
VEGF .64 .05 .8 27 .082 
TNFα .39 .05 .8 69 .358 
AR = Androgen Receptor; VEGF = Vascular endothelial growth factor; TNFa = Tumour necrosis factor 
alpha. 
a One-way ANOVA test. 
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Table S2: The characteristics of the selected antibodies. 
Antibody  clonality Isotype Host Reactivity Tissue 
specificity 
Catalog 
number 
company 
Anti-
Androgen 
Receptor 
clone 
AR441 
Monoclonal IgG Mouse Human Nucleus M3562 DAKO 
Anti-
VEGF 
clone 
VG1 
Monoclonal IgG Mouse Human Secreted M7273 DAKO 
Anti-
TNFa 
Polyclonal IgG Rabbit Mouse, Rat, Guinea 
pig, Human, Pig, 
Fish, Cynomolgus 
monkey 
Nucleus 
and 
cytoplasm 
Ab6671 Abcam 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
30 
30 
 
 
Table S3: The protocol used for AR (1:50), VEGF (1:100) and TNFa (1:200). 
Category Code Reagent Name Incubation  
1. Rinse  Buffer  
2. Enzyme Pre-treatment   FLEX TRIS High PH Solution  10min 97°C 
3. Rinse  Buffer  
4. Endogenous Enzyme Block SM801 FLEX Peroxidase Block 5min 
5. Rinse  Buffer  
6. Primary Antibody  FLEX Ab Diluent + 1° Ab  o/n 4°C 
7. Rinse  Buffer  
8. Secondary Reagent  SM804 FLEX + Mouse LINKER 
(LINKER; for VEGF only) 
15min 
9. Rinse  Buffer  
10. Labelled Polymer SM802 FLEX/HRP 20min 
11. Rinse  Buffer 5min 
12. Substrate-Chromogen SM803 FLEX DAB + Substrate-Chromogen  5min 
13. Rinse  Buffer  
14. Auxiliary  Copper-Sulphate 0.5% 5min 
15. Rinse  Buffer  
16. Counterstain SM806 FLEX Hematoxylin 5min 
17. Rinse  DI Water  
18. Rinse  Buffer 5min 
19. Rinse  DI Water  
 
